Dec 8 2011
Watson Pharmaceuticals, Inc. (NYSE: WPI) today announced that under a settlement with Teva Women's Health, Watson has launched Amethia® Lo (levonorgestrel/ethinyl estradiol (0.1mg/0.02mg) and ethinyl estradiol (0.01mg)) tablets, the generic equivalent of Teva Women's Health, Inc.'s LoSEASONIQUE®. Amethia® Lo tablets are indicated for the prevention of pregnancy.
As a "first applicant" to submit a substantially complete ANDA, Watson is eligible for 180 days of shared generic market exclusivity. For the most recent twelve months ending September 30, 2011, LoSEASONIQUE® had sales of approximately $28 million, according to IMS Health data.
Source:
Watson Pharmaceuticals, Inc.
Lancet Commission predicts sharp increase in global prostate cancer cases